N
Nelson B. Watts
Researcher at University of Cincinnati Academic Health Center
Publications - 215
Citations - 20940
Nelson B. Watts is an academic researcher from University of Cincinnati Academic Health Center. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 59, co-authored 209 publications receiving 18999 citations. Previous affiliations of Nelson B. Watts include Emory University & University of Texas Southwestern Medical Center.
Papers
More filters
Journal ArticleDOI
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial
Steven T. Harris,Nelson B. Watts,Harry K. Genant,Clark D. McKeever,Thomas N. Hangartner,Michael Keller,Charles H. Chesnut,Jacques P. Brown,Erik Fink Eriksen,Mohammad S. Hoseyni,Douglas Wayne Axelrod,Paul D. Miller +11 more
TL;DR: Risedronate, a potent bisphosphonate, has been shown to be effective in the treatment of Paget disease of bone and other metabolic bone diseases, but, to the knowledge, it has not been evaluated in this article.
Journal ArticleDOI
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
TL;DR: Each bisphosphonates has a unique profile that may help to explain potential clinical differences among them, in terms of their speed and duration of action, and effects on fracture reduction.
Journal ArticleDOI
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.
John A. Kanis,Anders Odén,Olof Johnell,Helena Johansson,C De Laet,Jacques P. Brown,Peter Burckhardt,Cyrus Cooper,Claus Christiansen,Steven R. Cummings,John A. Eisman,S. Fujiwara,C.-C. Glüer,David Goltzman,Didier Hans,M-A Krieg,A.Z. La Croix,Eugene V. McCloskey,Dan Mellström,Lee J. Melton,Huib A.P. Pols,Jonathan Reeve,Kerrie M. Sanders,A. M. Schott,Alan J. Silman,David J. Torgerson,T. P. van Staa,Nelson B. Watts,Noriko Yoshimura +28 more
TL;DR: BMD and clinical risk factors predict hip and other osteoporotic fractures with higher specificity and sensitivity than either alone and provide the basis for the integrated use of validated Clinical risk factors in men and women to aid in fracture risk prediction.
Journal ArticleDOI
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Nelson B. Watts,S. T. Harris,Harry K. Genant,Richard D. Wasnich,Paul D. Miller,Rebecca D. Jackson,A.A. Licata,Philip D. Ross,G C Woodson rd,M. J. Yanover +9 more
TL;DR: A prospective, two-year, double-blind, placebo-controlled, multicenter study in 429 women who had one to four vertebral compression fractures plus radiographic evidence of osteopenia to determine the effects of etidronate in the treatment of postmenopausal osteoporosis.
Journal ArticleDOI
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya Khan,Archie Morrison,David A. Hanley,Dieter Felsenberg,Laurie K. McCauley,Felice O'Ryan,Ian R. Reid,Salvatore L. Ruggiero,Akira Taguchi,Sotirios Tetradis,Nelson B. Watts,Maria Luisa Brandi,Edmund Peters,Teresa Guise,Richard Eastell,Angela M. Cheung,Suzanne N Morin,Basel Masri,Cyrus Cooper,Cyrus Cooper,Sarah L. Morgan,Barbara Obermayer-Pietsch,Bente L. Langdahl,Rana Al Dabagh,K. Shawn Davison,David L. Kendler,George K.B. Sándor,Robert G. Josse,Mohit Bhandari,Mohamed El Rabbany,D. D. Pierroz,Riad A. Sulimani,Deborah P. Saunders,Jacques P. Brown,Juliet E. Compston +34 more
TL;DR: In those patients at high risk for the development of ONJ, including cancer patients receiving high‐dose BP or Dmab therapy, consideration should be given to withholding antiresorptive therapy following extensive oral surgery until the surgical site heals with mature mucosal coverage.